



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/771,425	01/26/2001	Xaveer Van Ostade	4644US	8053
7590	02/13/2004		EXAMINER	
Allen C. Turner TRASK BRITT P.O. BOX 2550 Salt Lake City, UT 84110			LI, RUIXIANG	
			ART UNIT	PAPER NUMBER
			1646	

DATE MAILED: 02/13/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Advisory Action</b>	<b>Application No.</b>	<b>Applicant(s)</b>
	09/771,425	OSTADE ET AL.
	<b>Examiner</b>	<b>Art Unit</b>
	Ruixiang Li	1646

*--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --*

THE REPLY FILED on January 27, 2004 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.

**PERIOD FOR REPLY** [check either a) or b)]

a)  The period for reply expires 4 months from the mailing date of the final rejection.  
 b)  The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.  
 ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).

Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

1.  A Notice of Appeal was filed on \_\_\_\_\_. Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.
2.  The proposed amendment(s) will not be entered because:
  - (a)  they raise new issues that would require further consideration and/or search (see NOTE below);
  - (b)  they raise the issue of new matter (see Note below);
  - (c)  they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
  - (d)  they present additional claims without canceling a corresponding number of finally rejected claims.

NOTE: See Continuation Sheet.

3.  Applicant's reply has overcome the following rejection(s): \_\_\_\_\_.
4.  Newly proposed or amended claim(s) \_\_\_\_\_ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).
5.  The a) affidavit, b) exhibit, or c) request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet.
6.  The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.
7.  For purposes of Appeal, the proposed amendment(s) a) will not be entered or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.

The status of the claim(s) is (or will be) as follows:

Claim(s) allowed: \_\_\_\_\_.

Claim(s) objected to: \_\_\_\_\_.

Claim(s) rejected: 1-11, 14-16, 18 and 21-25.

Claim(s) withdrawn from consideration: \_\_\_\_\_.

8.  The drawing correction filed on \_\_\_\_\_ is a) approved or b) disapproved by the Examiner.

9.  Note the attached Information Disclosure Statement(s) ( PTO-1449) Paper No(s). \_\_\_\_\_.

10.  Other: \_\_\_\_\_.

Continuation of 2. NOTE: The amended claim 15 recites "contacting the eukaryotic cell with a ligand", which is confusing and renders the claim indefinite because the claim is drawn to a method of screening for ligands of an orphan receptor and only compounds to be screened should be contacted with the cell unless a competitive binding assay is used. Thus, "contacting the eukaryotic cell with a ligand" should be deleted. Instead, a step of measuring binding of a compound being to the orphan receptor should be added if there is support in the specification because a ligand, according to its definition, is required to bind to the receptor and activation of the reporter system does not necessarily indicate the test compound is a ligand.

In addition, the amended claims 24 and 35 recite "comparing the inhibiting activity of said series of compound to a control compound". It is unclear what are the metes and bounds of the claims because the term "a control compound" is not defined unambiguously in the specification. Thus, the amendment raises an issue of indefiniteness under 35 U.S.C. 112, 2nd paragraph.

Continuation of 5. does NOT place the application in condition for allowance because: (i) the rejection of claims 15, 16, 18, 24, and 25 under 35 USC 112, second paragraph, remains; (ii) the rejection of claims 1-11, 14-16, 18, and 21-25 under 35 U.S.C. 103 (a) also remains.

(i) Rejection of claims 15, 16, 18, 24, and 25 under 35 USC 112, second paragraph, remains because (i) Claim 15 has not been amended to include a step of measuring binding of the test compound to the receptor (claim 18 depends from claim 15); and (ii) new indefiniteness issue raised in claims 15, 16, 18, 24, and 25 by the proposed amendment.


Applicants argue that the activation or deactivation of the reporter system is all that is required to perform the screening. This is not persuasive because activation or deactivation of the reporter system is not an indicator of whether a compound (an antagonist) binds to a chimeric receptor.

(ii) Rejection of claims 1-11, 14-16, 18, and 21-25 under 35 U.S.C. 103 (a) remains. Applicants continue to argue that a *prima facie* case of obviousness cannot be established with regard to any of independent claims 1, 15, 24, or 25 since no suggestion or motivation exists to combine the cited references. This is not persuasive for the reasons set forth in the record (Paper No. 20 & 22).

(iii) If the amendment were entered, the rejection of claim 11 under 35 U.S.C. 112, 2nd paragraph would be overcome.

(iv) Information Disclosure Statement

The Information Disclosure Statement submitted on December 4, 2003 has been considered by the Examiner in view of Applicants' argument and a fee set forth in 1.17(p) has been charged.



GARY KUNZ  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 1600

Rwixiang hi 216/204

Serial No.: 09/771,425

U.S. Patent Documents

<u>U.S. Patent No.</u>	<u>Publication Date</u>	<u>Patentee</u>
RLi US - 5,283,173	02-01-1994	Fields et al.
RLi US - 6,326,150 B1	12-04-2001	Golemis et al.
RLi US - 6,332,897 B1	12-25-2001	Weiner et al.
RLi US - 6,406,863 B1	06-18-2002	Zhu et al.

This Supplemental Information Disclosure Statement is filed after the mailing date of the final Office Action under 37 C.F.R. § 1.113, but before payment of the issue fee.

I am informed and believe that no item of information contained in the Supplemental Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the statement. Pursuant to 37 C.F.R. § 1.97(d)(ii), applicant hereby requests consideration of the accompanying Supplemental Information Disclosure Statement. The fee pursuant to 37 C.F.R. § 1.17(p) for consideration of this Supplemental Information Disclosure Statement is enclosed.

Respectfully submitted,



Andrew F. Nilles  
Registration No. 47,825  
Attorney for Applicant(s)  
TRASKBRITT, P.C.  
P.O. Box 2550  
Salt Lake City, Utah 84110-2550  
Telephone: 801-532-1922

Date: December 1, 2003

AFN/bv

Enclosures: Form PTO-1449 or PTO/SB/08

Copy of documents cited

Check in the amount of \$180.00

Document in ProLaw